Berkeley Lights is a California-based company developing technologies in the forms of platforms and workflows to enable cell-by-cell selection and manipulation to allow for development, antibody discovery, and engineering for personalized therapies. Its technologies are designed to accelerate cell-based scientific discovery through their digital cell biology technology.
The company was founded in 2011 by Igor Khandros, William Davidow, and Ming Wu. Their digital cell biology technologies are used in biotherapeutic discovery and development, cellular therapy manufacturing, synthetic biology, biotechnology, agricultural biology, and life science.
The company has a platform called the Berkeley Lights Platform and it can be utilized to accelerate research using a database of cells with information such as relevant phenotypic characteristics . There are various platforms that can be used in areas including antibody discovery, cell line development, cell therapy development, and synthetic biology.
During the COVID-19 pandemic, researchers in China, Australia, and the United States utilized the company's Beacon platform to guide and isolate cells, which is used in the process of discovering antibodies for treatments of diseases and viruses such as COVID-19.
Eric Hobbs, Ph.D.
Berkeley Lights Closes $95 Million Funding Round To Expedite Commercial Expansion And Platform Development For Cell Therapy
Berkeley Lights, Inc.
October 15, 2018
How the coronavirus validated Berkeley Lights' technology and its supply chain
March 13, 2020